Toremifene-atamestane; alone or in combination: Predictions from the preclinical intratumoral aromatase model

Journal of Steroid Biochemistry and Molecular Biology

Volumn 108, Issue 1-2, 2008, Pages 1-7

  Sabnis, Gauri J ^a   Macedo, Luciana ^a   Goloubeva, Olga ^b   Schayowitz, Adam ^a   Zhu, Yue ^a   Brodie, Angela ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

Author keywords

Ac 1 cells; Antiestrogens; Aromatase inhibitors

Indexed keywords

ANTIESTROGEN; AROMATASE; AROMATASE INHIBITOR; ATAMESTANE; ESTROGEN RECEPTOR; TAMOXIFEN; TOREMIFENE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; IC 50; IN VITRO STUDY; MOUSE; NONHUMAN; OVARIECTOMY; POSTMENOPAUSE; SCID MOUSE;

ANDROSTENEDIONE; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE; BREAST NEOPLASMS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MICE; MICE, SCID; PROGNOSIS; TOREMIFENE; TRANSFECTION; TREATMENT OUTCOME; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS;

EID: 38649090033     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2007.04.005     Document Type: Article

References (27)

1. Gerken P. Toremifene citrate (Fareston). Clin. J. Oncol. Nurs. 8 (2004) 529-530
2. Kusama M., Miyauchi K., Aoyama H., Sano M., Kimura M., Mitsuyama S., Komaki K., and Doihara H. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer. Breast Cancer Res. Treat. 88 (2004) 1-8
3. el Etreby M.F. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review. J. Steroid Biochem. Mol. Biol. 44 (1993) 565-572
4. Lombardo M.E., Hakky S.I., and Hudson P.B. In vitro studies on the inhibition of testosterone synthesis in the human testis by atamestane. J. Steroid Biochem. Mol. Biol. 44 (1993) 287-290
5. Muller M., van den Beld A.W., van der Schouw Y.T., Grobbee D.E., and Lamberts S.W. Effects of dehydroepiandrosterone and atamestane supplementation on frailty in elderly men. J. Clin. Endocrinol. Metab. 91 10 (2006) 3988-3991
6. Gingell J.C., Knonagel H., Kurth K.H., Tunn U.W., and The Schering 90.062 Study Group. Placebo controlled double-blind study to test the efficacy of the aromatase inhibitor atamestane in patients with benign prostatic hyperplasia not requiring operation. J. Urol. 154 (1995) 399-401
7. Radlmaier A., Eickenberg H.U., Fletcher M.S., Fourcade R.O., Reis Santos J.M., van Aubel O.G., Bono A.V., and Atamestane Study Group. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Prostate 29 (1996) 199-208
8. Yue W., and Brodie A. MCF-7 human breast carcinomas in nude mice as a model for evaluating aromatase inhibitors. J. Steroid Biochem. Mol. Biol. 44 (1993) 671-673
9. Buzdar A., Douma J., Davidson N., Elledge R., Morgan M., Smith R., Porter L., Nabholtz J., Xiang X., and Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J. Clin. Oncol. 19 (2001) 3357-3366
10. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Jaenicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Chaudri-Ross H., Lang R., Wyld P., and Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J. Clin. Oncol. 21 (2003) 2101-2109
11. Mouridsen H., Gershanovich M., Sun Y., Perez-Carrion R., Boni C., Monnier A., Apffelstaedt J., Smith R., Sleeboom H.P., Janicke F., Pluzanska A., Dank M., Becquart D., Bapsy P.P., Salminen E., Snyder R., Lassus M., Verbeek J.A., Staffler B., Chaudri-Ross H.A., and Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J. Clin. Oncol. 19 (2001) 2596-2606
12. Thurlimann B., Hess D., Koberle D., Senn I., Ballabeni P., Pagani O., Perey L., Aebi S., Rochlitz C., and Goldhirsch A. Anastrozole ('Arimidex') versus tamoxifen as first-line therapy in postmenopausal women with advanced breast cancer: results of the double-blind cross-over SAKK trial 21/95-a sub-study of the TARGET (Tamoxifen or 'Arimidex' Randomized Group Efficacy and Tolerability) trial. Breast Cancer Res. Treat. 85 (2004) 247-254
13. Baum M., Budzar A.U., Cuzick J., Forbes J., Houghton J.H., Klijn J.G., and Sahmoud T. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
14. Brodie A., Jelovac D., and Long B.J. Predictions from a preclinical model: studies of aromatase inhibitors and antiestrogens. Clin. Cancer Res. 9 (2003) 455S-459S
15. Brodie A., Lu Q., Liu Y., Long B., Wang J.P., and Yue W. Preclinical studies using the intratumoral aromatase model for postmenopausal breast cancer. Oncology (Huntingt) 12 (1998) 36-40
16. Macedo L.F., Guo Z., Tilghman S.L., Sabnis G.J., Qiu Y., and Brodie A. Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res. 66 (2006) 7775-7782
17. Yue W., Zhou D., Chen S., and Brodie A. A new nude mouse model for postmenopausal breast cancer using MCF-7 cells transfected with the human aromatase gene. Cancer Res. 54 (1994) 5092-5095
18. Long B.J., Jelovac D., Thiantanawat A., and Brodie A.M. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model. Clin. Cancer Res. 8 (2002) 2378-2388
19. Long B.J., Jelovac D., Handratta V., Thiantanawat A., MacPherson N., Ragaz J., Goloubeva O.G., and Brodie A.M. Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J. Natl. Cancer Inst. 96 (2004) 456-465
20. Jelovac D., Macedo L., Handratta V., Long B.J., Goloubeva O.G., Ingle J.N., and Brodie A.M. Effects of exemestane and tamoxifen in a postmenopausal breast cancer model. Clin. Cancer Res. 10 (2004) 7375-7381
21. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Cameron D.A., Palmer M.J., and Pater J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J. Natl. Cancer Inst. 97 (2005) 1262-1271
22. Goss P.E., Ingle J.N., Martino S., Robert N.J., Muss H.B., Piccart M.J., Castiglione M., Tu D., Shepherd L.E., Pritchard K.I., Livingston R.B., Davidson N.E., Norton L., Perez E.A., Abrams J.S., Therasse P., Palmer M.J., and Pater J.L. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N. Engl. J. Med. 349 (2003) 1793-1802
23. Goss P.E., and Strasser K. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors. Drugs 62 (2002) 957-966
24. Goss P.E., and Strasser-Weippl K. Prevention strategies with aromatase inhibitors. Clin. Cancer Res. 10 (2004) 372S-379S
25. Baum M. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur. J. Cancer 38 (2002) 1984-1986
26. Goss P.E. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial. Semin. Oncol. 33 (2006) S8-S12
27. Dignam J.J., and Fisher B. Occurrence of stroke with tamoxifen in NSABP B-24. Lancet 355 (2000) 848-849